AXL and nonpapillary renal cell carcinoma: The synergistic effect of sAXL with pazopanib and axitinib could reduce the growth of xenograft derived from ccRCC patients, which supported the combination of AXL inhibitors and antiangiogenic agents in the treatment of ccRCC [74].